[Federal Register Volume 86, Number 55 (Wednesday, March 24, 2021)]
[Notices]
[Page 15642]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06064]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-23-2021]


Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico; Notification 
of Proposed Production Activity; IPR Pharmaceuticals, Inc.; 
(Pharmaceutical Products); Canovanas, Puerto Rico

    IPR Pharmaceuticals, Inc., (IPR Pharmaceuticals) submitted a 
notification of proposed production activity to the FTZ Board for its 
facility in Canovanas, Puerto Rico. The notification conforming to the 
requirements of the regulations of the FTZ Board (15 CFR 400.22) was 
received on March 15, 2021.
    IPR Pharmaceuticals already has authority to produce certain 
pharmaceutical products within FTZ 7. The current request would add a 
finished product and foreign status material to the scope of authority. 
Pursuant to 15 CFR 400.14(b), additional FTZ authority would be limited 
to the specific foreign-status material and specific finished product 
described in the submitted notification (as described below) and 
subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt IPR Pharmaceuticals 
from customs duty payments on the foreign-status materials/components 
used in export production. On its domestic sales, for the foreign-
status materials/components noted below and in the existing scope of 
authority, IPR Pharmaceuticals would be able to choose the duty rate 
during customs entry procedures that applies to FARXIGA\FORXIGA 
(dapagliflozin) tablets (duty-free). IPR Pharmaceuticals would be able 
to avoid duty on foreign-status components which become scrap/waste. 
Customs duties also could possibly be deferred or reduced on foreign-
status production equipment.
    The material sourced from abroad is dapagliflozin active 
pharmaceutical ingredient (duty rate 6.5%). The request indicates the 
foreign-status material is subject to duties under Section 301 of the 
Trade Act of 1974 (Section 301), depending on the country of origin. 
The applicable Section 301 decisions require subject merchandise to be 
admitted to FTZs in privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is May 3, 2021.
    A copy of the notification will be available for public inspection 
in the ``Reading Room'' section of the Board's website, which is 
accessible via www.trade.gov/ftz.
    For further information, contact Christopher Wedderburn at 
[email protected].

    Dated: March 19, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-06064 Filed 3-23-21; 8:45 am]
BILLING CODE 3510-DS-P